01.01.2006 | Clinical trial
Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer
Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2006
Einloggen, um Zugang zu erhalten